Item 2.02. Results of Operations and Financial Condition.
On July 15, 2021, Corvus Pharmaceuticals, Inc. ("Corvus" or the
"Company") issued a press release regarding, among other matters, certain of its
financial results for the second quarter of 2021. A copy of the press release
is furnished as Exhibit 99.1 to this Form 8-K.
The information in this Item 2.02 of this Form 8-K and the Exhibit
99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or
otherwise subject to the liabilities of that Section, or incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in
such a filing.
Item 8.01. Other Events.
On July 15, 2021, the Company announced that it has discontinued its
Phase 3 study of mupadolimab for COVID-19 due to positive trends exhibited by
COVID-19 vaccines in lowering serious infection and hospitalizations. The
discontinuation is not related to any safety or efficacy issues observed in
study patients. The Company will continue to advance the development of
mupadolimab in oncology, where it is currently being studied in a Phase 1/1b
clinical trial. In particular, the Company announced that it is now enrolling
an expansion cohort for HPV+ head and neck cancer and its goal is to present
initial results from this cohort at a medical meeting later this year.
Item 9.01. Financial Statements and Exhibits.
Exhibit No. Description
99.1 Press release of Corvus Pharmaceuticals, Inc.
dated July 15, 2021.
104 Cover Page Interactive Data File (embedded within the Inline
© Edgar Online, source Glimpses